clinical research prime

Intranasal RSV
- 24-59 months of age.
- A Phase 1/2a Trial of the Safety, Tolerability and Immunogenicity of PIV5-vectored RSV Vaccine in RSV Seropositive Children.
- Participants will receive study related treatment at no cost and will be compensated for time and travel.

Senior RSV 60+
- A Phase 3 Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Respiratory Syncytial Virus (RSV) Vaccine in Adults 60 Years of Age or Older.
- Participants will receive study related treatment at no cost and will be compensated for time and travel.